TY - JOUR
T1 - Antibiotic overuse for COVID-19; are we adding insult to injury?
AU - Abdela, Seid Getahun
AU - Liesenborghs, Laurens
AU - Tadese, Fentaw
AU - Abegaz, Seid Hassen
AU - Bayuh, Fentaw Bialfew
AU - Asmamaw, Etsegenet Arega
AU - Mebratie, Tamiru Asefa
AU - Mamo, Abreham Eshetu
AU - Mebrate, Maraki Assefa
AU - Embiale, Wendemaegn
AU - Hunegnaw, Samuel
AU - Hundie, Dereje Bedanie
AU - Hurissa, Zewdu
AU - Agero, Gebi
AU - Kaso, Abdene Weya
AU - van Henten, Saskia
AU - van Griensven, Johan
N1 - FTX; OGOA; (CC BY 4.0)
PY - 2021
Y1 - 2021
N2 - In this study, we described the proportion of COVID-19 patients started on antibiotics empirically and the work-ups performed to diagnose bacterial superinfection. We used a retrospective cohort study design involving medical records of symptomatic, hospitalized COVID-19 patients who were admitted to these centers. A total of 481 patients were included, with a median age of 41.0 years (interquartile range, 28-58.5 years). A total of 72.1% (N = 347) of COVID-19 patients received antibiotics, either before or during admission. This is troublesome because none of the patients' bacterial culture or inflammatory markers, such as the erythrocyte sedimentation rate or C-reactive protein, were evaluated, and only 73 (15.2%) underwent radiological investigations. Therefore, national COVID-19 guidelines should emphasize the rational use of antibiotics for the treatment of COVID-19, a primarily viral disease. Integrating antimicrobial stewardship into the COVID-19 response and expanding microbiological capacities in low-income countries are indispensable. Otherwise, we risk one pandemic aggravating another.
AB - In this study, we described the proportion of COVID-19 patients started on antibiotics empirically and the work-ups performed to diagnose bacterial superinfection. We used a retrospective cohort study design involving medical records of symptomatic, hospitalized COVID-19 patients who were admitted to these centers. A total of 481 patients were included, with a median age of 41.0 years (interquartile range, 28-58.5 years). A total of 72.1% (N = 347) of COVID-19 patients received antibiotics, either before or during admission. This is troublesome because none of the patients' bacterial culture or inflammatory markers, such as the erythrocyte sedimentation rate or C-reactive protein, were evaluated, and only 73 (15.2%) underwent radiological investigations. Therefore, national COVID-19 guidelines should emphasize the rational use of antibiotics for the treatment of COVID-19, a primarily viral disease. Integrating antimicrobial stewardship into the COVID-19 response and expanding microbiological capacities in low-income countries are indispensable. Otherwise, we risk one pandemic aggravating another.
U2 - 10.4269/ajtmh.21-0603
DO - 10.4269/ajtmh.21-0603
M3 - A1: Web of Science-article
C2 - 34715676
SN - 0002-9637
VL - 105
SP - 1519
EP - 1520
JO - American Journal of Tropical Medicine and Hygiene
JF - American Journal of Tropical Medicine and Hygiene
IS - 6
ER -